Pharma Partnering EU 2026: Biotech BD&L Trends to Watch
Pharma Partnering EU Summit 2026 in Basel focuses on business development and licensing, featuring one-to-one meetings and discussions on oncology, immunology, and AI.
Key Takeaways
- Pharma Partnering EU Summit 2026 will convene in Basel, Switzerland, focusing on business development and licensing.
- The summit will feature pre-arranged one-to-one meetings, company presentations, and panel discussions to foster collaborations.
- Discussions are expected to highlight recent clinical data in oncology, immunology, and rare diseases, reflecting current partnering trends.
- Keep an eye on key players like Boehringer Ingelheim, Zai Lab, AbbVie, and Eli Lilly, who have been active in recent partnering deals.
The Pharma Partnering EU Summit 2026 is set to take place on May 20–21, 2026, in Basel, Switzerland. This event will concentrate on business development and licensing (BD&L), providing a platform for global pharmaceutical and biotech leaders to connect, explore potential collaborations, and drive innovation in the industry.
Pharma Partnering EU Summit 2026 is designed to facilitate strategic alliances, licensing agreements, and investments within the pharmaceutical and biotech sectors. The summit will feature pre-arranged one-to-one meetings, allowing senior executives to engage in focused discussions. Company presentations will showcase assets and technologies, while panel discussions will address industry trends, emerging therapies, and global strategies. While specific late-breaking abstracts are not yet available, the agenda promises valuable insights into the evolving landscape of pharmaceutical partnerships.
Partnering Themes
Discussions at the summit will likely address recent positive clinical data readouts, particularly in high-interest areas such as oncology, immunology, and rare diseases. Recent partnering deals in Q1 2026 indicate a strong focus on oncology and the integration of artificial intelligence (AI) in drug development. Companies such as Boehringer Ingelheim, Zai Lab, AbbVie, and Eli Lilly have been actively involved in these deals, signaling key areas of interest for potential partnerships.
For example, Cosmo Pharma announced positive Phase III data for clascoterone in androgenetic alopecia (AGA). Eli Lilly's Jaypirca (pirtobrutinib) extended progression-free survival (PFS) in previously treated CLL/SLL. GSK reported positive data for a B7-H4-targeted ADC. IDEAYA/Servier had positive data for darovasertib in metastatic uveal melanoma (mUM). Revolution Medicines announced positive Phase III data for rasonrasib in oncology. Spyre Therapeutics reported positive Phase II data for SPY001 in ulcerative colitis. SynOx Therapeutics had positive Phase III data for emactuzumab in tenosynovial giant cell tumor (TGCT). AbbVie's Elahere (mirvetuximab soravtansine) succeeded in a Phase II PSOC trial. Genmab presented updated Phase I/II data for rinatabart sesutacan, an epcoritamab-related ADC. These clinical advancements are expected to drive partnering discussions.
Companies to Watch
Several companies have been particularly active in recent partnering deals and should be closely watched at the event. These include Boehringer Ingelheim, Zai Lab, AbbVie, Eli Lilly, Regeneron, and GSK. Presentations from companies showcasing their assets and technologies will be a key component of the summit. Additionally, insights from leaders at companies like Astellas Pharma Europe, Bayer, and NTC Pharma will provide valuable perspectives on the evolution of pharmaceutical partnerships.
Market & Investor Implications
The Pharma Partnering EU Summit serves as a barometer for investment and partnering trends in the pharmaceutical industry. The focus on oncology, AI, and innovative therapies reflects the current priorities of investors and pharmaceutical companies. Positive clinical data readouts and strategic collaborations announced at the summit can significantly impact market valuations and investor confidence.
What to Watch Next
As the event approaches, keep an eye out for the release of the detailed agenda, including specific company presentations and panel discussions. Monitoring news and press releases from participating companies will provide insights into potential deals and collaborations that may emerge from the summit. Also of note are other EU-focused partnering events in 2026, including Outsourcing in Clinical Trials (OCT) Europe and Digi-Tech Pharma & AI.
Frequently Asked Questions
What is the focus of the Pharma Partnering EU Summit 2026?
The summit focuses on business development and licensing (BD&L) within the pharmaceutical and biotech industries, facilitating partnerships, licensing agreements, and investments.
Where and when will the summit take place?
The summit is scheduled for May 20–21, 2026, in Basel, Switzerland.
What types of activities will be featured at the summit?
The summit will include pre-arranged one-to-one meetings, company presentations showcasing assets and technologies, and panel discussions on industry trends and strategies.
Which companies should I watch at the summit?
Keep an eye on companies active in recent partnering deals, such as Boehringer Ingelheim, Zai Lab, AbbVie, Eli Lilly, Regeneron, and GSK.
What are some key themes expected to be discussed?
Key themes will likely include recent clinical data in oncology, immunology, and rare diseases, as well as the integration of AI in drug development.
